Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 17 Feb 2017
At a glance
- Drugs Brentuximab vedotin (Primary) ; Carboplatin; Etoposide; Ifosfamide
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 07 Feb 2017 Planned End Date changed from 1 Jan 2017 to 1 Sep 2017.
- 01 Feb 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Sep 2017.
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology